Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 126,394

Document Document Title
WO/2017/062568A1
The invention relates to methods of determining if a subject is at risk of developing post-traumatic stress disorder (PTSD).  
WO/2017/062270A1
Methods of diagnosis and methods of treatment and prevention for autism spectrum disorder are provided using decoy antigens to maternal brain-reactive antibodies.  
WO/2017/060290A1
The present invention relates to a crystalline forms of encenicline hydrochloride and a process for their preparation. The invention also concerns a pharmaceutical compositions comprising an effective amount of the crystalline form of en...  
WO/2017/060406A1
The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3Kβ in...  
WO/2017/062238A1
The present invention provides methods and compositions for diagnosing and treating intellectual disability (ID). The invention also provides methods and compositions for developing and using in-vitro and in vivo models for diagnosis and...  
WO/2017/059486A1
The present invention relates to compositions and methods for the treatment of epilepsy. In particular, the present invention relates to the use of muramyl dipeptide crosslinked to form a microparticle for reducing the frequency and/or s...  
WO/2017/060202A1
The present invention relates to compounds of formula I; wherein R1' is CH3 R1 is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1 and R1 may form together a l,l-dioxo-tetrahydro-thiophen-3-yl ring; R is hydrogen, methyl, ethyl, is...  
WO/2017/060750A1
The invention relates to the use of a composition from a plant extract of Withania somnifera, to treat or limit development of pathologies of the myelin, including multiple sclerosis disease.  
WO/2017/062682A2
The present invention concerns methods for treating multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use.  
WO/2017/061125A1
The present invention provides a therapeutic agent or prophylactic agent for psoriasis, multiple sclerosis, and reduction of side effects caused by TLR-base/IMQ/immunostimulatory adjuvants. It was found that CARD14 is linked to psoriasis...  
WO/2017/062924A1
Dosing regimens and methods are disclosed for upregulating protein kinase C (PKC) while reducing subsequent downregulation, comprising administering a PKC activator once a week for three consecutive weeks followed by cessation of adminis...  
WO/2017/061534A1
The present invention provides a compound which has an effect of inhibiting amyloid β production, especially an effect of inhibiting BACE1, and which is useful as a therapeutic or prophylactic agent for diseases induced by production, s...  
WO/2017/055481A1
Disclosed are compositions containing an extract of Curcuma spp, optionally as curcumin in the form of a complex with phospholipids, and a lipophilic extract of Zingiber officinale, for use in the treatment of osteoarthritis.  
WO/2017/057562A1
The present invention provides a therapeutic agent and/or a prophylactic agent and the like for a peripheral nerve disorder or a spinal injury having zonisamide or an alkali metal salt thereof as an active ingredient.  
WO/2017/058689A1
The invention is directed to novel anhydrous crystalline butenedioate salt form 1 of Compound I, which is a modulator of muscarinic M1 receptors. The novel crystalline forms of compound I are useful in the treatment or prevention of Alzh...  
WO/2017/057717A1
Provided is a heteroaromatic derivative which is represented by general formula (I), has an OX receptor antagonistic activity and is useful as a therapeutic or prophylactic drug for diseases mediated by an OX receptor, or a pharmaceutica...  
WO/2017/055592A1
The invention provides compound that inhibit or modulate the activity of p70S6 kinase, the compounds being of the formula (I) or a salt, tautomer or N-oxide thereof; wherein: one of Y and Z is R3 and the other is Ar2; Q1 is an optionally...  
WO/2017/055632A1
Trilobine and its natural triple-bridged bisbenzylisoquinoline alkaloidal analogues as DNMT inhibitors for use as a drug for the treatment of cancer and neurological diseases and for cell reprogramming, in particular to prime for chemoth...  
WO/2017/055337A1
The present invention relates to an aqueous composition comprising apomorphine or a pharmaceutically acceptable salt or solvate thereof, reduced glutathione (GSH) or a pharmaceutically acceptable salt thereof, and ascorbic acid or a phar...  
WO/2017/059113A1
The present disclosure provides methods and compositions for the treatment, identification, diagnosis, and prognosis of dystonia, or dystonia related disorders.  
WO/2017/059118A1
The present disclosure provides methods and compositions for the treatment, identification, diagnosis, and prognosis of dystonia, or dystonia related disorders.  
WO/2017/056338A1
The present invention provides a method for producing a compound represented by formula (I). Thereby provided is a 4-heteroaryl-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl) -1H-pyrazole-5-carboxylic acid amide derivative.  
WO/2017/054640A1
The present invention provides a use of tetrahydropalmatine in preparing an anti-cisplatin toxicity medicament, the toxicity comprising renal toxicity, ototoxicity, and neurotoxicity.  
WO/2017/055533A1
(Formula I) Compounds of formula (I) usefull for the treatment of cancer, neurodegenerative disorders and metabolic disorders.  
WO/2017/059106A1
The disclosure provides methods for treating psychiatric diseases, such as schizophrenia, in patients with certain gene polymorphisms using antipsychotic drugs, such as risperidone and paliperidone.  
WO/2017/059385A1
Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium chan...  
WO/2017/058691A1
This invention provides novel processes for the preparation of compounds such as 3-[(1S,2S)-2-hydroxycyclohexyl]-6-[(6-methylpyridin-3-yl)met hyl]benzo[h]-quinazolin-4(3H)-one, salts and derivatives thereof. The compounds synthesized by ...  
WO/2017/056092A1
A method of promoting nerve growth or regeneration in a subject in need thereof, wherein the subject is not afflicted with a substantial connective tissue damage, is provided. The method comprises administering to the subject a therapeut...  
WO/2017/054786A1
The present invention relates to an improved production method of 1-(4-fluorobenzyl)-3-(4--isobutoxybenzyl)-1-(1--methylpiperi din-4-yl)urea (Pimavanserin), an inverse agonist of the serotonin 5-HT2A receptor of formula (I). Crude pimava...  
WO/2017/055530A1
(Formula I) Compounds of formula (I) usefull for the treatment of cancer, neurodegenerative disorders and metabolic disorders.  
WO/2017/059385A8
Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium chan...  
WO/2017/051423A1
The invention relates to compositions and formulations comprising at least one triterpenoic acid and at least one neutral triterpenoid and uses thereof for treating for use in treating a condition selected from Alzheimer's disease (AD), ...  
WO/2017/053613A1
Disclosed herein are methods of treating and preventing neuronal cell loss in a subject using ornithine in combination with phenylacetate or phenylbutyrate. In some embodiments, the subject has received or will receive a surgical procedu...  
WO/2017/052455A1
A composition comprising one or more effective fragments of an amylase, for use as a medicament or a dietary supplement, in particular for the treatment of hyperglycemic conditions, conditions involving hyperinsulinemia and conditions in...  
WO/2017/050803A1
The present invention relates to an agent which inhibits Kallikrein-8 for use in the treatment or prevention of Alzheimer's disease and / or its precursor stages, as well as to methods, kits and uses relating thereto, including diagnosti...  
WO/2017/051046A1
The invention relates to the use of a group of compounds with a phenothiazine nucleus of general formula (I) for the treatment of diseases of the central nervous system which present synapse abnormalities, such as autism or fragile X syn...  
WO/2017/050259A1
Provided are prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.  
WO/2017/049411A1
Disclosed herein are methods and compositions for increasing and decreasing the permeability of the blood brain barrier for the treatment of diseases and conditions and to facilitate the delivery of agents to the brain, as well as method...  
WO/2017/051294A1
The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, wherein the variables R1, R2 and R3 are as defin...  
WO/2017/050791A8
The invention provides novel compounds having the general formula (I) wherein R1, R2,Y, W, m, n, p and q are as defined herein, compositions including the compounds and methods of using the compounds.  
WO/2017/053842A1
The invention provides methods for the treatment of seizures and epilepsy using FGF21 receptor activators.  
WO/2017/050791A1
The invention provides novel compounds having the general formula (I) wherein R1, R2,Y, W, m, n, p and q are as defined herein, compositions including the compounds and methods of using the compounds.  
WO/2017/053613A8
Disclosed herein are methods of treating and preventing neuronal cell loss in a subject using ornithine in combination with phenylacetate or phenylbutyrate. In some embodiments, the subject has received or will receive a surgical procedu...  
WO/2017/051585A1
[Problem] To provide an inhaling fragrance that can be taken in other than through oral administration. [Solution] The inhaling fragrance includes leaf alcohol and linalool, includes ethanol as a primary solvent, and is liquid at normal ...  
WO/2017/050171A1
Provided are crystal forms I, II, III and IV of a pyrroloquinoline quinone sodium salt and a preparation method thereof. Also provided are a pharmaceutical composition, a cosmetic composition, a functional food or a nutritional agent con...  
WO/2017/051303A1
The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula (I), wherein the variables R1, R2, R3, R4 and X are...  
WO/2017/050807A1
The present invention relates to pyridyl or pyrazinyl compounds carrying a methyl- bound N-amide moiety derived from an α-amino acid of formula I where the variables are as defined in the claims and the description. The invention furthe...  
WO/2017/051276A1
The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula (I), and the variables R1, R2 and R3 are as defined...  
WO/2017/051188A1
Methods for the prevention and treatment of neurodegenerative diseases, in particular motor neuron diseases such as amyotrophic lateral sclerosis (ALS), is described, as well as compositions and combined preparations for use in the metho...  
WO/2017/053346A1
The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously a...  

Matches 701 - 750 out of 126,394